Abstract
The selective κ opioid receptor agonist nalfurafine was launched in 2009 as an antipruritic drug for patients undergoing hemodialysis. It is the first clinically used compound with high selectivity for the κ opioid receptor. Nalfurafine had a different pharmacological feature from other κ opioid agonists. Nalfurafine induced neither addictive nor aversive effects, whereas other κ agonists such as U- 50,488H or salvinorin A produced psychotomimetic effects like dysphoria. Therefore, identification of the essential structural moieties of nalfurafine for binding to the κ opioid receptor was important for elucidation of the pharmacological discrepancies observed with these κ opioid agonists. Based on the investigations of various nalfurafine derivatives, the essential structural moieties of nalfurafine were unveiled. Both the nitrogen substituted by a cyclopropylmethyl group and the 6-amide side chain were indispensable. The phenol ring was important for obtaining strong binding affinities for the opioid receptors, but not indispensable for exerting selectivity for the κ receptor. This structure-activity information is expected to lead to the development of novel κ opioid receptor selective agonists.
Keywords: Opioid receptor, κ opioid receptor, agonist, nalfurafine, address part, U-50, 488H, active conformation.
Current Pharmaceutical Design
Title:Essential Structure of the κ Opioid Receptor Agonist Nalfurafine for Binding to the κ Receptor
Volume: 19 Issue: 42
Author(s): Hiroshi Nagase and Hideaki Fujii
Affiliation:
Keywords: Opioid receptor, κ opioid receptor, agonist, nalfurafine, address part, U-50, 488H, active conformation.
Abstract: The selective κ opioid receptor agonist nalfurafine was launched in 2009 as an antipruritic drug for patients undergoing hemodialysis. It is the first clinically used compound with high selectivity for the κ opioid receptor. Nalfurafine had a different pharmacological feature from other κ opioid agonists. Nalfurafine induced neither addictive nor aversive effects, whereas other κ agonists such as U- 50,488H or salvinorin A produced psychotomimetic effects like dysphoria. Therefore, identification of the essential structural moieties of nalfurafine for binding to the κ opioid receptor was important for elucidation of the pharmacological discrepancies observed with these κ opioid agonists. Based on the investigations of various nalfurafine derivatives, the essential structural moieties of nalfurafine were unveiled. Both the nitrogen substituted by a cyclopropylmethyl group and the 6-amide side chain were indispensable. The phenol ring was important for obtaining strong binding affinities for the opioid receptors, but not indispensable for exerting selectivity for the κ receptor. This structure-activity information is expected to lead to the development of novel κ opioid receptor selective agonists.
Export Options
About this article
Cite this article as:
Nagase Hiroshi and Fujii Hideaki, Essential Structure of the κ Opioid Receptor Agonist Nalfurafine for Binding to the κ Receptor, Current Pharmaceutical Design 2013; 19 (42) . https://dx.doi.org/10.2174/138161281942140105165011
DOI https://dx.doi.org/10.2174/138161281942140105165011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Liver Cancer Somatic Mutations on Protein Structures and Functions
Current Proteomics Synthesis and Anticancer Properties of Novel Truncated Carbocyclic Nucleoside Analogues
Anti-Cancer Agents in Medicinal Chemistry Application of Multivariate Linear and Nonlinear Calibration and Classification Methods in Drug Design
Combinatorial Chemistry & High Throughput Screening Ganoderma lucidum (Ling-zhi): The Impact of Chemistry on Biological Activity in Cancer
Current Bioactive Compounds Modulation of GABAA Receptors by Natural Products and the Development of Novel Synthetic Ligands for the Benzodiazepine Binding Site
Current Drug Targets Synthesis and Preliminary Biological Evaluation of New Heterocyclic Carboxamide Models
Letters in Drug Design & Discovery Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Studies on Two New Mixed Ligand Platinum Compounds with a Trans- Geometry
Medicinal Chemistry Synthesis, Molecular Docking and Biological Evaluation of Novel Flavone Derivatives as Potential Anticancer Agents Targeting Akt
Medicinal Chemistry Pharmacotherapeutic Potential of Garlic in Age-Related Neurological Disorders
CNS & Neurological Disorders - Drug Targets Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer
Current Gene Therapy Surface Plasmon Resonance Imaging Sensor for Cathepsin Determination Based on Immobilized Cystatin
Protein & Peptide Letters Advances in the Integration of Drug Metabolism into the Lead Optimization Paradigm
Mini-Reviews in Medicinal Chemistry Phycocyanin from Arthrospira platensis. Production, Extraction and Analysis
Current Biotechnology Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology Recent Progress in Patterned Silicon Nanowire Arrays: Fabrication, Properties and Applications
Recent Patents on Nanotechnology Chemical Advances in Therapeutic Application of Exosomes and Liposomes
Current Medicinal Chemistry Metallodendrimers and Dendrimer Nanocomposites
Current Pharmaceutical Design NAD Biosynthesis in Humans - Enzymes, Metabolites and Therapeutic Aspects
Current Topics in Medicinal Chemistry